Effective October 1, 2024, Shinyaku Research Center, Inc. and Anpaku Center, Inc. merged, and the merged entity changed its name to TransGenic, Inc.
Below is a description of the pre-merger information.
NDRcenter is a contract research organization with extensive experience in evaluating the pharmacological effects of pharmaceuticals. This page provides an overview of the company’s non-clinical capabilities, examples of disease models, and representative study cases. We hope you can use this information for a reference when selecting a CRO for your non-clinical needs.
NDRcenter provides GLP(Good laboratory Practice) non-clinical studies. This ensures clients with highly reliable data. The company offers a wide range of safety study in general toxicity, reproductive/developmental toxicity studies. These rigorous safety evaluation are essential during the development of pharmaceutical drugs and medical devices.
NDRcenter provides a wide range of non-clinical studies in pharmaceutical drugs, medical devices, and foods. They are particularly known for their flexibility in handling a variety of safety studies —such as skin sensitization and cytotoxicity assays —they will provide an efficient, one-stop-for-all service for a variety of study types.
They offer biochemical testing and histopathological evaluation with the team of experienced specialists. The company also has a dedicated quality assurance department to ensure the delivery of accurate and reliable data: detailed analysis and in-depth evaluation that is tailored to each client’s research needs.
It is essential to go through the testing of candidate compounds in animal models that reproduce the target disease before advancing to clinical trials.
However, clinically relevant disease models may not always exist, thus there are demands for animal models with strong clinical correlation.
Below are some examples of disease models offered at Ina Research.
This model carries the UMAI-Luc gene, in which luciferase acts as a reporter, enabling visualization of the translational induction of ATF4—a key regulator of stress-response gene expression. These mice serve as a valuable tool for time-course observation of stress responses.
This model uses luciferase as a reporter and allows visualization of endoplasmic reticulum stress caused by the accumulation of unfolded or misfolded proteins during protein synthesis. The ERAI gene enables luminescent detection of stressed cells.
To establish a mice model of multiple sclerosis, antigen emulsions were injected subcutaneously at two sites, followed by intraperitoneal administration of PTX solution. Another PTX dose was given 22–26 hours later. After the initial PTX administration, mice received either vehicle or the test substance orally once daily. As a result, co-administration with the adjuvant successfully induced the EAE model.
Research in the central nervous system requires sophisticated techniques and evaluation systems. Using brain microdialysis in freely moving rats and mice, NDRcenter collected extracellular molecules and measured neurotransmitter release in the brain. This technique has been applied to assess fluctuations in neurotransmitters following administration of antidepressants and anxiolytics, as well as to evaluate changes in target substances under specific experimental conditions.
NDRcenter is a CRO that conducts a wide range of studies in pharmaceuticals, medical devices, chemicals, foods, and other fields.
| Address | 1-7-1 Yurakucho, Chiyoda-ku, Tokyo |
|---|---|
| Tel | 0120-34-0412 |
| Website | http://www.ndrcenter.co.jp/ |
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.